These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 24599409

  • 1. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer.
    Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, Parrilla P.
    Ann Surg Oncol; 2014 Jul; 21(7):2383-9. PubMed ID: 24599409
    [Abstract] [Full Text] [Related]

  • 2. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
    Cascales-Campos PA, Gil J, Feliciangeli E, Gil E, González-Gil A, López V, Ruiz-Pardo J, Nieto A, Parrilla JJ, Parrilla P.
    Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W, Sardi A, Nieroda C, Sittig M, Milovanov V, Nunez M, Aydin N, Gushchin V.
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [Abstract] [Full Text] [Related]

  • 5. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer.
    Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P.
    Ann Surg Oncol; 2012 Jul; 19(7):2352-9. PubMed ID: 20039210
    [Abstract] [Full Text] [Related]

  • 6. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S.
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [Abstract] [Full Text] [Related]

  • 7. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [Abstract] [Full Text] [Related]

  • 12. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M, Vaira M, Marsanic P, Mellano A, Borsano A, Cinquegrana A, Sottile A, De Simone M.
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [Abstract] [Full Text] [Related]

  • 13. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
    Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spilioitis J, Torres-Melero J, Turaga K, Trout R.
    Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493
    [Abstract] [Full Text] [Related]

  • 14. Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Pedro Antonio CC, Álvaro Jesús GR, José G, Elena G, Alida G, Francisco ML, Guillermo CDC, Pascual P.
    Surg Oncol; 2019 Mar; 28():57-61. PubMed ID: 30851912
    [Abstract] [Full Text] [Related]

  • 15. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G, Ferreira FO, Mantoan H, da Costa AA, Faloppa CC, Kumagai LY, de Mello CA, Takahashi RM, Nakagawa WT, Aguiar S, Lopes A.
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [Abstract] [Full Text] [Related]

  • 16. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N, Förtsch T, Aladashvili A, Hohenberger W, Croner RS.
    World J Surg Oncol; 2016 Feb 24; 14(1):42. PubMed ID: 26912149
    [Abstract] [Full Text] [Related]

  • 17. Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
    Cascales-Campos P, López-López V, Gil J, Arévalo-Pérez J, Nieto A, Barceló F, Gil E, Parrilla P.
    Surg Oncol; 2016 Sep 24; 25(3):164-70. PubMed ID: 27566018
    [Abstract] [Full Text] [Related]

  • 18. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
    Sinukumar S, Damodaran D, Ray M, Mehta S, Paul L, Bhatt A.
    Eur J Surg Oncol; 2021 Jun 24; 47(6):1427-1433. PubMed ID: 33509612
    [Abstract] [Full Text] [Related]

  • 19. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study.
    Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, Oger AS, Dravet F, Jaffre I, Classe JM.
    Ann Surg Oncol; 2014 Oct 24; 21(11):3621-7. PubMed ID: 24819120
    [Abstract] [Full Text] [Related]

  • 20. Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients.
    Cascales-Campos P, Gil J, Gil E, Feliciangeli E, López V, Gonzalez AG, Ruiz-Pardo J, Nieto A, Parrilla P.
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug 24; 179():88-93. PubMed ID: 24965986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.